EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting CIC::DUX4 sarcoma with Minnelide in a dual recombinase–initiated genetically engineered mouse model

MaKenna R Browne, Axel V Silver, Risha Banerjee, Brendan C Dickson, Benigno Aquino, Kristianne M Oristian, Jonathon Himes, Peter G Hendrickson, David G Kirsch

Journal of Clinical Investigation · 15.07.2026 · 136 (14)

DOI: 10.1172/jci202218 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 16.06.2026. Verfasst von MaKenna R Browne und 8 weiteren Autor:innen. Beteiligte Einrichtung: Cell and Molecular Biology Program, and. Hauptthemen laut MEDLINE: Homeodomain Proteins, Sarcoma, Neoplasm Proteins. Die Arbeit nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NICHD NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CIC::DUX4 sarcoma (CDS) is a lethal cancer driven by a fusion between the tumor suppressor capicua (CIC) and the pioneer transcription factor double homeobox 4 (DUX4). We previously generated 3 genetically engineered mouse models (GEMMs) of CDS with CIC::DUX4 regulated by loxP-STOP-loxP cassettes, however, mice from all 3 models developed spontaneous tumors without Cre recombinase. Here, we established a next-generation GEMM of CDS (dual-flex [dFLEx] CDS) that used a dual recombinase (Cre plus the thermostable mutant of FLP recombinase FLPE) FLEx-switch design to activate CIC::DUX4 expression and initiate sarcomagenesis in a spatially and temporally controlled manner. Because CIC::DUX4 drives sarcoma development by activating an oncogenic transcriptional program, we performed a drug screen on human-derived CDS cell lines using a library of compounds that modulate transcription. This screen identified Minnelide, an inhibitor of RNA polymerase II–mediated transcription, as a selective inhibitor of CDS. Mechanistically, Minnelide acted through xeroderma pigmentosum type B to alter phosphorylation of RPB1, the largest subunit of RNA polymerase II. Subsequently, RPB1 underwent degradation leading to apoptosis of CDS cells. Minnelide demonstrated in vivo efficacy in dFLEx CDS GEMMs and in human CDS xenografts. As Minnelide has already been demonstrated to be safe in clinical trials, these findings identify Minnelide as a potential therapeutic option to test in patients with CDS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Homeodomain ProteinsSarcomaNeoplasm ProteinsAnimalsMiceHumansMice, TransgenicCell Line, TumorDisease Models, AnimalIntegrases

Stichwörter der Autor:innen

Cell biologyDrug screensMouse modelsOncologyTranscription

Substanzen

Homeodomain ProteinsDux4 protein, mouseNeoplasm ProteinsIntegrases

Autor:innen und Institutionen

  • Cell and Molecular Biology Program, and.
  • Developmental and Stem Cell Biology Program, Duke University Medical Center, Durham, North Carolina, USA.
  • Department of Radiation Oncology.
  • Department of Medical Biophysics, and.
  • Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
  • Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada.

Förderung

  • NCI NIH HHS
  • NICHD NIH HHS
  • National Cancer Institute
  • U.S. Department of Defense
  • Conquer Cancer, The ASCO Foundation and QuadW Foundation
  • Alex’s Lemonade Stand Foundation
  • National Institute of Child Health and Development

Zitieren

APA

Browne, M. R., Silver, A. V., Banerjee, R., Dickson, B. C., Aquino, B., Oristian, K. M., Himes, J., Hendrickson, P. G., & Kirsch, D. G. (2026). Targeting CIC::DUX4 sarcoma with Minnelide in a dual recombinase–initiated genetically engineered mouse model. Journal of Clinical Investigation, 136(14). https://doi.org/10.1172/jci202218

Vancouver

Browne MR, Silver AV, Banerjee R, Dickson BC, Aquino B, Oristian KM, et al. Targeting CIC::DUX4 sarcoma with Minnelide in a dual recombinase–initiated genetically engineered mouse model. Journal of Clinical Investigation. 2026;136(14). doi:10.1172/jci202218

BibTeX
@article{Browne2026,
  author = {Browne, MaKenna R and Silver, Axel V and Banerjee, Risha and Dickson, Brendan C and Aquino, Benigno and Oristian, Kristianne M and Himes, Jonathon and Hendrickson, Peter G and Kirsch, David G},
  title = {Targeting CIC::DUX4 sarcoma with Minnelide in a dual recombinase–initiated genetically engineered mouse model},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  volume = {136},
  number = {14},
  doi = {10.1172/jci202218}
}
Kostenlos starten →